Navigation Links
VIVUS to Present at Four Upcoming Healthcare Conferences
Date:9/1/2009

MOUNTAIN VIEW, Calif., Sept. 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at four healthcare investment conferences during the month of September.

The conference presentation schedule is as follows:

        Rodman & Renshaw Annual Global Investment Conference
        September 10, 2009 at 10:50 a.m. ET
        The New York Palace Hotel, New York, NY

        Thomas Weisel Partners Healthcare Conference
        September 11, 2009 at 11:30 a.m. ET
        The Four Seasons Hotel, Boston, MA

        BioCentury's NewsMakers in the Biotech Industry Conference
        September 16, 2009 at 3:30 p.m. ET
        Millennium Broadway Hotel & Conference Center, New York, NY

        UBS Global Life Sciences Conference
        September 21, 2009 at 3:30 p.m. ET
        Grand Hyatt, New York, NY

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:
    Timothy E. Morris
    Chief Financial Officer
    VIVUS, Inc.
    +1-650-934-5200,

    Brian Korb
    Investor Relations
    The Trout Group,
    +1-646-378-2923

    Sheryl Seapy
    Media Relations
    Pure Communications, Inc.
    +1-949-608-0841


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. VIVUS to Present at the Needham and Company Life Sciences Conference
3. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
4. VIVUS Reports First Quarter 2009 Financial Results and Highlights
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
6. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
7. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. Beckman Coulter to Present at Upcoming Healthcare Conferences
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
Breaking Biology News(10 mins):